Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2024-12-24 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). It specifically details a 'Decision on Paid-in Capital Increase' (유상증자결정), outlining the number of shares, pricing, subscription dates, and allocation methods. This falls under the category of capital structure changes and financing activities.
2024-12-24 Korean
증권신고서(지분증권) (2025.02)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed by AdBiotech Co., Ltd. with the Financial Services Commission (FSC) in South Korea. It contains detailed information regarding the offering of securities, including investment risks, business overview, and financial status. This is a formal regulatory filing required for public offerings of securities, which falls under the category of Regulatory Filings (RNS) as it is a primary regulatory document that does not fit into the other specific categories like 10-K or Earnings Release.
2024-12-24 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as an amendment ('정정신고') to a previous filing regarding stock option grants. In the context of corporate filings, announcements regarding the issuance or modification of stock options, warrants, or equity-based compensation plans are classified under 'Share Issue/Capital Change' (SHA) as they represent changes to the company's capital structure and potential future equity dilution.
2024-12-17 Korean
[기재정정]주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding a correction to a previously filed 'Stock Option Grant' report (주식매수선택권 부여에 관한 신고). It details changes in the number of shares granted and the list of recipients due to employee resignations. Since this is a specific regulatory disclosure regarding equity-based compensation and capital structure changes that does not fit into the other specific categories like 'Director's Dealing' or 'Share Issue', it is classified as a general Regulatory Filing.
2024-12-17 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to previously granted stock options, including the number of shares and the list of recipients. In the context of corporate filings, reports regarding the issuance or modification of stock options (equity-based compensation) are classified under 'Regulatory Filings' (RNS) as they do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2024-12-17 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of a corporate action related to shareholder rights. Given the nature of the announcement as a regulatory disclosure of a record date, it fits best under the general regulatory filing category.
2024-12-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.